Chuangyebang was informed that recently, Jiangsu Hanbang Technology Co., Ltd. (referred to as: Hanbang Technology) announced the completion of the C round of financing of over 300 million yuan. This round of financing was led by China Life Equity. This round of financing will help the company continue to increase its production capacity in the field of chromatographic separation and purification, and expand its product distribution in the field of innovative therapies.
Founded in 1998, Hanbang Technology is currently the largest manufacturer of liquid chromatography equipment in China. In the process of fighting against the epidemic, the company has vigorously transformed production workshops and increased production capacity, which has provided a strong guarantee for the launch of my country’s new crown vaccine. At present, the company has formed a business matrix covering separation and purification systems and chromatographic separation media for macromolecular drugs and small molecule drugs, from laboratory to pilot production to industrial production. At the same time, it has independent innovative chromatography technology platforms such as supercritical fluid chromatography system and simulated moving bed continuous chromatography system. It is a rare supplier in China that can provide customers with integrated solutions and services centered on chromatography products.
In the field of innovative therapy core process equipment and consumables, the company continues to increase investment layout to better meet the needs of emerging markets such as small nucleic acid drugs, mRNA drugs, cell therapy, and gene therapy for high-quality domestic process equipment and consumables in the upstream industry. Among them, the core process equipment for small nucleic acid drugs (such as laboratory to industrial-grade nucleic acid synthesizers, etc.) and gene and cell drugs have been recognized by well-known domestic enterprises.
China Life Equity stated that high-end equipment is at the core of the value chain and industrial chain, determines the comprehensive competitiveness of the entire industrial chain, and is an important engine for promoting industrial transformation and upgrading. China Life Equity hopes to join hands with Hanbang Technology to continuously increase investment in research and development, constantly break through technical barriers, provide the market with diversified chromatographic separation solutions, reduce the constraints of imported products or technologies, and at the same time build a key technology pedigree with Made in China and Created in China The production system will help the high-quality development of my country’s biopharmaceutical industry.
media coverage
China Investment Network Venture Capital
This article is reprinted from: https://readhub.cn/topic/8gOa3bdcH8G
This site is for inclusion only, and the copyright belongs to the original author.